

# Deborah J Donnell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2676023/publications.pdf>

Version: 2024-02-01

197  
papers

12,883  
citations

29994

54  
h-index

27345

106  
g-index

203  
all docs

203  
docs citations

203  
times ranked

9816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. <i>New England Journal of Medicine</i> , 2012, 367, 399-410.	13.9	2,665
2	Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. <i>Lancet, The</i> , 2010, 375, 2092-2098.	6.3	844
3	Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 19-26.	4.6	375
4	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
5	Bacterial Vaginosis Associated with Increased Risk of Female-to-Male HIV-1 Transmission: A Prospective Cohort Analysis among African Couples. <i>PLoS Medicine</i> , 2012, 9, e1001251.	3.9	306
6	HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 340-348.	0.9	270
7	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	13.9	270
8	Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 77ra29.	5.8	265
9	Effect of Universal Testing and Treatment on HIV Incidence – HPTN 071 (PopART). <i>New England Journal of Medicine</i> , 2019, 381, 207-218.	13.9	255
10	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. <i>Lancet, The</i> , 2019, 394, 303-313.	6.3	230
11	Childhood Sexual Abuse Is Highly Associated With HIV Risk-Taking Behavior and Infection Among MSM in the EXPLORE Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 340-348.	0.9	222
12	Increased risk of HIV-1 transmission in pregnancy. <i>Aids</i> , 2011, 25, 1887-1895.	1.0	219
13	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. <i>PLoS Medicine</i> , 2013, 10, e1001511.	3.9	192
14	The Effect of Psychosocial Syndemic Production on 4-Year HIV Incidence and Risk Behavior in a Large Cohort of Sexually Active Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 329-336.	0.9	166
15	Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1 Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. <i>PLoS Medicine</i> , 2016, 13, e1002099.	3.9	166
16	Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations. <i>Journal of Virology</i> , 2007, 81, 7885-7893.	1.5	149
17	Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 32-43.	0.5	148
18	The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. <i>Social Science and Medicine</i> , 2009, 68, 740-748.	1.8	147

#	ARTICLE	IF	CITATIONS
19	Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. <i>The Lancet Global Health</i> , 2014, 2, e267-e277.	2.9	141
20	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. <i>PLoS ONE</i> , 2010, 5, e12598.	1.1	129
21	Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. <i>Aids</i> , 2013, 27, 2155-2160.	1.0	124
22	Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET1The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.1. <i>Drug and Alcohol Dependence</i> , 1999, 53, 197-205.	1.6	115
23	Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 362.	3.8	110
24	Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients. <i>JAMA Internal Medicine</i> , 2017, 177, 1083.	2.6	105
25	Seroadaptive Practices: Association with HIV Acquisition among HIV-Negative Men Who Have Sex with Men. <i>PLoS ONE</i> , 2012, 7, e45718.	1.1	103
26	Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 1021-1028.	4.6	95
27	A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002292.	3.9	95
28	HIV Incidence Determination in the United States: A Multiassay Approach. <i>Journal of Infectious Diseases</i> , 2013, 207, 232-239.	1.9	94
29	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1055-1064.	4.6	94
30	HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model. <i>PLoS ONE</i> , 2014, 9, e84511.	1.1	91
31	PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003670.	3.9	87
32	Recent Patterns in Population-Based HIV Prevalence in Swaziland. <i>PLoS ONE</i> , 2013, 8, e77101.	1.1	86
33	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86
34	Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. <i>JAMA Internal Medicine</i> , 2015, 175, 246.	2.6	83
35	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 606-608.	0.9	81
36	Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1211-8.	1.9	80

#	ARTICLE	IF	CITATIONS
37	Genomewide Association Study for Determinants of HIV-1 Acquisition and Viral Set Point in HIV-1 Serodiscordant Couples with Quantified Virus Exposure. PLoS ONE, 2011, 6, e28632.	1.1	80
38	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV, 2017, 4, e83-e92.	2.1	78
39	Early Human Immunodeficiency Virus (HIV) Infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: Risk Behaviors, Symptoms, and Early Plasma and Genital Tract Virus Load. Journal of Infectious Diseases, 2001, 183, 23-35.	1.9	77
40	The dynamic relationship between social norms and behaviors: the results of an HIV prevention network intervention for injection drug users. Addiction, 2013, 108, 934-943.	1.7	77
41	Persistence of K103N-Containing HIV Variants after Single-Dose Nevirapine for Prevention of Mother-to-Child Transmission. Journal of Infectious Diseases, 2007, 195, 711-715.	1.9	75
42	Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. PLoS ONE, 2011, 6, e25828.	1.1	75
43	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. Aids, 2017, 31, 2007-2016.	1.0	75
44	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Research, 2017, 1, 3.	2.0	75
45	Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. Aids, 2010, 24, 737-744.	1.0	72
46	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Journal of Infectious Diseases, 2021, 224, 1581-1592.	1.9	72
47	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Research, 2017, 1, 3.	2.0	71
48	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Scientific Reports, 2021, 11, 15531.	1.6	70
49	Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. , 2022, 1, .		69
50	Serosorting Is Associated with a Decreased Risk of HIV Seroconversion in the EXPLORE Study Cohort. PLoS ONE, 2010, 5, e12662.	1.1	66
51	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV, 2020, 7, e229-e237.	2.1	66
52	Relationships between social norms, social network characteristics, and HIV risk behaviors in Thailand and the United States.. Health Psychology, 2009, 28, 323-329.	1.3	65
53	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
54	Substance Use Among Men Who Have Sex With Men: Comparison With a National Household Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 86-90.	0.9	59

#	ARTICLE	IF	CITATIONS
55	Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 374-380.	0.9	57
56	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 522-529.	0.9	56
57	Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. <i>Aids</i> , 2007, 21, 1165-1174.	1.0	52
58	Comparison of a High-Resolution Melting Assay to Next-Generation Sequencing for Analysis of HIV Diversity. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3054-3059.	1.8	52
59	Daily Oral Tenofovir and Emtricitabine—Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1—Uninfected Men and Women. <i>Annals of Internal Medicine</i> , 2014, 161, 11.	2.0	51
60	Isoflavonoid feeding deterrents for <i>Costelytra zealandica</i> Structure ? Activity relationships. <i>Journal of Chemical Ecology</i> , 1985, 11, 1713-1735.	0.9	48
61	Use of Non-Occupational Post-Exposure Prophylaxis does not Lead to an Increase in High Risk Sex Behaviors in Men Who have Sex with Men Participating in the EXPLORE Trial. <i>AIDS and Behavior</i> , 2010, 14, 1182-1189.	1.4	47
62	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1—Serodiscordant Couples. <i>Journal of Infectious Diseases</i> , 2015, 211, 1451-1460.	1.9	47
63	Predictors of HIV Transmission Risk Behavior and Seroconversion Among Latino Men Who have Sex with Men in Project EXPLORE. <i>AIDS and Behavior</i> , 2012, 16, 608-617.	1.4	44
64	Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. <i>Lancet HIV</i> , 2017, 4, e449-e456.	2.1	44
65	Cross-Sectional HIV Incidence Estimation in HIV Prevention Research. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S233-S239.	0.9	43
66	Specificity of Four Laboratory Approaches for Cross-Sectional HIV Incidence Determination: Analysis of Samples from Adults with Known Nonrecent HIV Infection from Five African Countries. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1177-1183.	0.5	40
67	Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. <i>Journal of Infectious Diseases</i> , 2016, 214, 1050-1057.	1.9	40
68	Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. <i>Aids</i> , 2014, 28, 2771-2776.	1.0	38
69	Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. <i>Aids</i> , 2014, 28, 1825-1830.	1.0	37
70	Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. <i>The Lancet Global Health</i> , 2017, 5, e1133-e1141.	2.9	37
71	Daily Short Message Service Surveys to Measure Sexual Behavior and Pre-exposure Prophylaxis Use Among Kenyan Men and Women. <i>AIDS and Behavior</i> , 2013, 17, 2977-2985.	1.4	36
72	HIV-1 Tropism and Survival in Vertically Infected Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2008, 197, 1382-1388.	1.9	33



#	ARTICLE	IF	CITATIONS
91	Scale-Up of PrEP integrated in public health HIV care clinics: a protocol for a stepped-wedge cluster-randomized rollout in Kenya. <i>Implementation Science</i> , 2018, 13, 118.	2.5	25
92	A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 680-687.	0.9	25
93	Analysis of HIV Diversity Using a High-Resolution Melting Assay. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 913-918.	0.5	24
94	Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. <i>Aids</i> , 2016, 30, 31-35.	1.0	24
95	Development of parallel measures to assess HIV stigma and discrimination among people living with HIV, community members and health workers in the HPTN 071 (PopART) trial in Zambia and South Africa. <i>Journal of the International AIDS Society</i> , 2019, 22, e25421.	1.2	24
96	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq0 0.0rgBT /Overlock 10 Tf	0.7	23
97	Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. <i>Contemporary Clinical Trials</i> , 2012, 33, 1280-1286.	0.8	23
98	Long-Term Follow-Up of Children in the HIVNET 012 Perinatal HIV Prevention Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 464-471.	0.9	23
99	Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. <i>Journal of the International AIDS Society</i> , 2017, 20, 21780.	1.2	23
100	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq0 0.0rgBT /Overlock 10 Tf	0.7	23
101	Quantifying Ongoing HIV-1 Exposure in HIV-1 Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1. <i>Journal of Infectious Diseases</i> , 2012, 206, 1299-1308.	1.9	22
102	Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, e65-e69.	0.9	21
103	Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 446-452.	0.9	21
104	Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. <i>American Journal of Epidemiology</i> , 2015, 182, 848-856.	1.6	21
105	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya. <i>Trials</i> , 2019, 20, 396.	0.7	20
106	The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. <i>Value in Health</i> , 2019, 22, 194-202.	0.1	20
107	HIV prevention trial design in an era of effective pre-exposure prophylaxis. <i>HIV Clinical Trials</i> , 2017, 18, 177-188.	2.0	19
108	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREATment and Monitoring (STREAM) study. <i>BMJ Open</i> , 2017, 7, e017507.	0.8	19

#	ARTICLE	IF	CITATIONS
109	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV</i> , 2019, 6, e475-e482.	2.1	19
110	Impact of Mutation Type and Amplicon Characteristics on Genetic Diversity Measures Generated Using a High-Resolution Melting Diversity Assay. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 130-137.	1.2	18
111	Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 119-128.	0.9	18
112	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 1534-1540.	1.9	18
113	Adaptive non-inferiority margins under observable non-constancy. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3318-3332.	0.7	18
114	Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25491.	1.2	18
115	Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa. <i>Tropical Medicine and International Health</i> , 2020, 25, 1246-1260.	1.0	18
116	Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial. <i>The Lancet Global Health</i> , 2021, 9, e668-e680.	2.9	18
117	Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S130-S134.	0.9	17
118	Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. <i>Sexually Transmitted Infections</i> , 2021, 97, 249-255.	0.8	17
119	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25731.	1.2	17
120	Use of HIV Case Surveillance System to Design and Evaluate Site-Randomized Interventions in an HIV Prevention Study: HPTN 065. <i>Open AIDS Journal</i> , 2012, 6, 122-130.	0.1	17
121	Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. <i>The Lancet Global Health</i> , 2021, 9, e1730-e1739.	2.9	17
122	Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. <i>Aids</i> , 2007, 21, 2077-2082.	1.0	16
123	<i>In Utero</i> HIV Infection Is Associated with an Increased Risk of Nevirapine Resistance in Ugandan Infants Who Were Exposed to Perinatal Single Dose Nevirapine. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 673-677.	0.5	16
124	Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study. <i>Lancet HIV</i> , 2021, 8, e495-e501.	2.1	16
125	Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants. <i>PLoS ONE</i> , 2011, 6, e18642.	1.1	16
126	Frequency of False Positive Rapid HIV Serologic Tests in African Men and Women Receiving PrEP for HIV Prevention: Implications for Programmatic Roll-Out of Biomedical Interventions. <i>PLoS ONE</i> , 2015, 10, e0123005.	1.1	15

#	ARTICLE	IF	CITATIONS
127	Assessment of Contamination and Misclassification Biases in a Randomized Controlled Trial of a Social Network Peer Education Intervention to Reduce HIV risk Behaviors Among Drug Users and Risk Partners in Philadelphia, PA and Chiang Mai, Thailand. <i>AIDS and Behavior</i> , 2015, 19, 1818-1827.	1.4	15
128	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. <i>Journal of Infectious Diseases</i> , 2015, 211, 1943-1952.	1.9	15
129	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15
130	Experience in international clinical research: the HIV Prevention Trials Network. <i>Clinical Investigation</i> , 2011, 1, 1609-1618.	0.0	14
131	Differential Regulatory T Cell Activity in HIV Type 1-Exposed Seronegative Individuals. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1321-1329.	0.5	14
132	Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. <i>AIDS and Behavior</i> , 2017, 21, 2173-2179.	1.4	14
133	Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078. <i>Journal of the International AIDS Society</i> , 2019, 22, e25246.	1.2	14
134	In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?. <i>Aids</i> , 2018, 32, 809-818.	1.0	13
135	Regional differences between people who inject drugs in an <sc>HIV</sc> prevention trial integrating treatment and prevention (<sc>HPTN</sc> 074): a baseline analysis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25195.	1.2	13
136	Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial. <i>Trials</i> , 2022, 23, .	0.7	13
137	Use of a High Resolution Melting Assay to Analyze HIV Diversity in HIV-infected Ugandan Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e222-e228.	1.1	12
138	HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission. <i>Aids</i> , 2014, 28, 235-243.	1.0	12
139	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. <i>Journal of Virology</i> , 2016, 90, 9855-9861.	1.5	12
140	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. <i>Clinical Infectious Diseases</i> , 2021, 72, 486-489.	2.9	12
141	Ethical considerations for new HIV prevention trials. <i>Lancet HIV;the</i> , 2019, 6, e489-e491.	2.1	11
142	Are there adverse consequences of quizzing during informed consent for HIV research?. <i>Journal of Medical Ethics</i> , 2011, 37, 693-697.	1.0	10
143	Correlation Between Pill Counts and Biologic Effects in an HIV-1 Prevention Clinical Trial: Implications for Measuring Adherence. <i>AIDS and Behavior</i> , 2013, 17, 632-639.	1.4	10
144	Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. <i>AIDS and Behavior</i> , 2013, 17, 3108-3119.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Understanding the HIV Epidemic Among MSM in Baltimore: A Modeling Study Estimating the Impact of Past HIV Interventions and Who Acquired and Contributed to Infections. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 253-262.	0.9	9
146	Analysis of HIV Tropism in Ugandan Infants. <i>Current HIV Research</i> , 2010, 8, 498-503.	0.2	8
147	Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa. <i>Clinical Trials</i> , 2011, 8, 103-111.	0.7	8
148	Herpes Simplex Virus Type 2 Acquisition Among HIV-1â€“Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 907-910.	1.9	8
149	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 158-165.	0.9	8
150	Determination of HIV status and identification of incident HIV infections in a large, communityâ€“randomized trial: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2020, 23, e25452.	1.2	8
151	High Incidence Is Not High Exposure: What Proportion of Prevention Trial Participants Are Exposed to HIV?. <i>PLoS ONE</i> , 2015, 10, e0115528.	1.1	8
152	Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial. <i>PLoS ONE</i> , 2022, 17, e0266665.	1.1	8
153	Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. <i>Aids</i> , 2022, 36, 1151-1159.	1.0	8
154	Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 701-705.	0.5	7
155	Challenges in the Design of HIV Prevention Trials in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, S136-S140.	0.9	7
156	Pregnancy Does Not Affect HIV Incidence Test Results Obtained Using the BED Capture Enzyme Immunoassay or an Antibody Avidity Assay. <i>PLoS ONE</i> , 2010, 5, e13259.	1.1	7
157	HIV Surveillance in a Large, Community-Based Study: Results from the Pilot Study of Project Accept (HIV Prevention Trials Network 043). <i>BMC Infectious Diseases</i> , 2011, 11, 251.	1.3	7
158	Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. <i>Drug and Alcohol Dependence</i> , 2014, 142, 139-145.	1.6	7
159	Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 430-438.	0.9	7
160	Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 249-255.	2.9	7
161	Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 423-429.	0.9	7
162	Validation of populationâ€“level HIVâ€“1 incidence estimation by crossâ€“sectional incidence assays in the HPTN 071 (PopART) trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25830.	1.2	7

#	ARTICLE	IF	CITATIONS
163	Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART). <i>PLoS ONE</i> , 2021, 16, e0258644.	1.1	7
164	Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa. <i>Journal of Clinical Virology</i> , 2015, 62, 75-79.	1.6	6
165	Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 300-303.	0.9	6
166	Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the US. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	0.9	6
167	Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. <i>Aids</i> , 2006, 20, 637.	1.0	5
168	Mortality Among Injection Drug Users in Northern Thailand: A Prospective Cohort Study. <i>Journal of Addiction Medicine</i> , 2010, 4, 217-222.	1.4	5
169	Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 81-90.	0.6	5
170	CD101 genetic variants modify regulatory and conventional T <sup>H</sup> cell phenotypes and functions. <i>Cell Reports Medicine</i> , 2021, 2, 100322.	3.3	5
171	PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial. <i>PLoS Computational Biology</i> , 2021, 17, e1009301.	1.5	5
172	High Levels of Viral Suppression Among East African HIV-Infected Women and Men in Serodiscordant Partnerships Initiating Antiretroviral Therapy with High CD4 Counts and During Pregnancy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 140-147.	0.5	4
173	Positive Social Impacts Related to Participation in an HIV Prevention Trial Involving People Who Inject Drugs. <i>IRB: Ethics &amp; Human Research</i> , 2015, 37, 17-9.	0.8	4
174	How can progress towards Ending the HIV Epidemic in the United States be monitored?. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	4
175	Association between rectal gonorrhoea and HIV incidence in men who have sex with men: a meta-analysis. <i>Sexually Transmitted Infections</i> , 2022, 98, 492-496.	0.8	4
176	High HIV incidence among young women in South Africa: Data from a large prospective study. <i>PLoS ONE</i> , 2022, 17, e0269317.	1.1	4
177	Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 38-43.	0.9	3
178	Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 350-357.	0.9	3
179	Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 300-307.	0.9	3
180	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.4	3

#	ARTICLE	IF	CITATIONS
181	Designing the Next Generation of HIV Prevention Efficacy Trials: Synopsis of a 2018 Symposium. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	3
182	Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. <i>Lancet HIV</i> , 2021, 8, e723-e728.	2.1	3
183	Sample size calculation for active-arm trial with counterfactual incidence based on recency assay. <i>Statistical Communications in Infectious Diseases</i> , 2021, 13, .	0.2	3
184	HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	3
185	Changing Antiretroviral Eligibility Criteria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 338-344.	0.9	2
186	Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
187	Brief Report: Bacterial Vaginosis and Risk of HIV Infection in the Context of CD101 Gene Variation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 584-587.	0.9	2
188	Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	1
189	Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents. <i>Journal of Infectious Diseases</i> , 2020, 221, 172-174.	1.9	1
190	Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. <i>Epidemics</i> , 2020, 33, 100423.	1.5	1
191	Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 632-640.	0.5	1
192	Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1147-1149.	1.0	1
193	Choosing a metric for measurement of pre-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , 2014, 14, 1177.	4.6	0
194	Supporting Research Sites in Resource-Limited Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, S44-S49.	0.9	0
195	Sexual Behaviors After PrEP Discontinuation Among HIV Serodiscordant Couples in Kenya and Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 174-181.	0.9	0
196	Reducing the Global HIV Burden: The Importance of Uneven Exposure to the Results of HIV Prevention Trials. <i>Mathematics of Planet Earth</i> , 2021, , 217-239.	0.1	0
197	Practical issues in operationalizing the design and outcome evaluation of cluster randomized trials. <i>Clinical Trials</i> , 2022, , 174077452210874.	0.7	0